novel
coronaviru
infect
coronaviru
diseas
emerg
wuhan
hubei
provinc
china
spread
mani
countri
worldwid
effort
made
develop
vaccin
human
coronaviru
cov
infect
mer
sar
past
decad
howev
date
licens
antivir
treatment
vaccin
exist
mer
sar
effort
develop
cov
vaccin
drug
target
spike
glycoprotein
protein
major
induc
neutral
antibodi
although
candid
shown
efficaci
vitro
studi
mani
progress
random
anim
human
trial
henc
may
limit
use
counter
infect
articl
highlight
ongo
advanc
design
vaccin
therapeut
counter
also
focus
experi
advanc
made
earlier
sarsand
merscov
togeth
could
enabl
effort
halt
emerg
viru
infect
articl
histori
coronavirus
cov
positivesens
singlestrand
rna
virus
famili
coronavirida
subfamili
coronavirina
infect
wide
host
rang
produc
diseas
rang
common
cold
severefat
ill
novel
viru
initi
name
chang
coronaviru
studi
group
csg
intern
committe
taxonomi
virus
ictv
sinc
found
sister
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
ongo
coronaviru
threat
emerg
china
rapidli
spread
countri
declar
global
health
emerg
world
health
organ
mani
nation
divert
best
effort
implement
appropri
prevent
control
strategi
neither
vaccin
directact
antivir
drug
avail
treatment
human
anim
coronaviru
infect
mani
effort
direct
develop
vaccin
human
cov
infect
recent
decad
limit
factor
degre
crossprotect
render
vaccin
due
extens
sequenc
divers
variou
vaccin
immunotherapeut
drug
option
explor
recent
threat
zika
ebola
nipah
virus
well
previou
cov
includ
sarsand
merscov
valuabl
option
exploit
potenc
efficaci
safeti
along
expedit
ongo
research
discov
valuabl
modal
tackl
emerg
yet
effect
vaccin
therapeut
intens
effort
ongo
therapeut
option
avail
manag
base
previou
experi
treat
sarsand
merscov
major
reason
lack
approv
commerci
avail
vaccin
therapeut
agent
cov
might
rel
lack
interest
among
pharmaceut
compani
outbreak
scenario
demand
drug
vaccin
last
period
outbreak
last
number
affect
peopl
also
small
proport
global
drug
vaccin
market
time
new
drug
vaccin
develop
might
patient
clinic
trial
also
meaning
market
newli
discov
drug
accord
guidelin
infect
patient
receiv
support
care
includ
oxygen
therapi
fluid
therapi
antibiot
treat
secondari
bacteri
infect
also
recommend
isol
patient
suspect
confirm
major
therapeut
drug
might
effect
manag
includ
remdesivir
lopinavirritonavir
alon
combin
convalesc
plasma
mab
nevertheless
util
drug
pneumonia
patient
clinic
efficaci
safeti
studi
conduct
articl
describ
advanc
design
vaccin
therapeut
counter
also
discuss
experi
sarsand
merscov
togeth
could
pave
way
right
direct
halt
emerg
viru
multipl
strategi
adopt
develop
cov
vaccin
target
surfaceexpos
spike
glycoprotein
protein
major
induc
neutral
antibodi
sever
sproteinbas
strategi
attempt
develop
cov
vaccin
eg
use
fulllength
protein
domain
rbd
express
viruslik
particl
vlp
dna
viral
vector
protein
molecul
contain
two
subunit
subunit
rbd
interact
host
cell
receptor
angiotensinconvert
enzym
wherea
subunit
mediat
fusion
viru
host
cell
membran
releas
viral
rna
cytoplasm
replic
henc
sproteinbas
vaccin
induc
antibodi
block
viral
receptor
bind
also
viru
genom
uncoat
shown
ctermin
domain
subunit
porcin
deltacoronaviru
constitut
immunodomin
region
immun
respons
region
show
potent
neutral
effect
protein
major
role
induct
protect
immun
infect
sarscov
elicit
neutralizingantibodi
tcell
respons
thu
fulllength
appropri
part
glycoprotein
believ
promis
candid
cov
vaccin
composit
also
report
neither
absenc
presenc
structur
protein
affect
protein
immunogen
bind
receptor
critic
initi
step
viru
access
host
cell
due
superior
abil
rbd
induc
neutral
antibodi
recombin
protein
contain
rbd
recombin
vector
encod
rbd
use
develop
effect
sarscov
vaccin
recombin
adenovirusbas
vaccin
express
merscov
protein
induc
system
igg
secretori
iga
lungresid
memori
tcell
respons
administ
intranas
balbc
mice
provid
longlast
neutral
immun
mer
spike
pseudotyp
viru
therebi
suggest
vaccin
may
confer
protect
merscov
furthermor
rabi
viru
rv
viral
vector
well
gramposit
enhanc
matrix
gem
bacteri
vector
use
express
merscov
protein
immun
respons
vaccin
candid
evalu
balbc
mice
cellular
humor
immun
respons
show
rvbase
vaccin
stimul
significantli
higher
level
cellular
immun
earlier
antibodi
respons
comparison
gem
particl
vector
possibl
develop
univers
cov
vaccin
assess
base
similar
tcell
epitop
sarsand
merscov
confirm
potenti
crossreact
among
cov
share
high
genet
similar
sarscov
vaccin
develop
sarscov
may
exhibit
crossreact
compar
evalu
perform
fulllength
protein
sequenc
sarscov
identifi
variabl
residu
locat
subunit
protein
critic
cov
vaccin
target
find
suggest
specif
neutral
antibodi
effect
sarscov
might
effect
even
though
protein
key
mutat
compar
sarscov
still
act
viabl
target
vaccin
develop
likewis
close
similar
sarscov
suggest
receptor
might
sarscov
receptor
immunoinformat
approach
use
identif
epitop
inclus
vaccin
candid
recent
immunoinformat
use
identifi
signific
cytotox
lymphocyt
ctl
bcell
epitop
protein
interact
epitop
correspond
mhc
class
molecul
studi
use
molecular
dynam
simul
found
ctl
epitop
bind
mhc
class
peptidebind
groov
via
multipl
contact
thu
indic
potenti
gener
immun
respons
epitop
may
possess
ideal
characterist
becom
part
vaccin
candid
nucleocapsid
n
protein
well
potenti
b
cell
epitop
e
protein
merscov
suggest
probabl
immunoprotect
target
induc
tcell
neutral
antibodi
respons
revers
genet
strategi
success
use
liveattenu
vaccin
inactiv
exonucleas
effect
nonstructur
protein
delet
envelop
protein
sar
avian
infecti
bronchiti
viru
ibv
chicken
cov
suggest
avian
live
viru
ibv
vaccin
strain
h
might
use
sar
given
protect
provid
strain
h
base
neutral
antibodi
product
well
immun
respons
henc
avian
ibv
vaccin
may
consid
anoth
option
evalu
safeti
monkey
scientist
rocki
mountain
laboratori
collabor
oxford
univers
develop
chimpanze
adenovirusvector
vaccin
candid
coalit
epidem
prepared
innov
cepi
recent
announc
initi
three
program
aim
develop
vaccin
util
establish
vaccin
platform
among
three
program
two
continu
previous
initi
partnership
cepi
collabor
inovio
develop
dna
vaccin
candid
mer
fund
vaccin
develop
util
dna
medicin
platform
deliv
synthet
gene
cell
translat
antigen
protein
elicit
tcell
antibodi
respons
cepi
collabor
univers
queensland
develop
molecular
clamp
vaccin
platform
multipl
viral
pathogen
includ
merscov
fund
vaccin
platform
function
synthes
viral
surfac
protein
get
attach
host
cell
clamp
shape
facilit
easier
recognit
antigen
immun
system
ongo
program
cepi
announc
fund
moderna
compar
mrna
therapeut
vaccin
design
manufactur
mrna
vaccin
collabor
vaccin
research
center
vrc
nation
institut
allergi
infecti
diseas
niaid
part
nation
institut
health
nih
niaidvrc
scientist
develop
vaccin
candid
express
protein
mrna
vaccin
platform
technolog
vaccin
expect
undergo
clinic
test
come
month
direct
administr
monoclon
antibodi
mab
may
play
effect
role
cov
control
intervent
expos
individu
observ
patient
recov
sar
display
potent
neutral
antibodi
respons
clinic
trial
propos
use
set
mab
function
target
specif
domain
merscov
protein
mab
bind
six
specif
epitop
group
interact
receptor
bind
membran
fusion
sialic
acidbind
site
repres
three
import
entri
function
merscov
protein
moreov
passiv
immun
poorli
potent
neutral
antibodi
induc
substanti
protect
mice
subject
lethal
merscov
challeng
thu
use
antibodi
may
repres
novel
approach
increas
humor
protect
emerg
cov
target
variou
protein
epitop
function
crossneutr
capac
sarscov
rbdspecif
neutral
mab
greatli
depend
similar
rbd
sarscov
rbdspecif
antibodi
crossneutr
sarslik
sl
cov
ie
batslcov
strain
rbd
amino
acid
differ
sarscov
batslcov
strain
amino
acid
differ
crossneutr
sarscov
rbdspecif
mab
evalu
efficaci
requir
compar
analysi
rbd
sarscov
suitabl
rbdspecif
mab
identifi
evalu
clinic
trial
regeneron
tri
identifi
mab
specif
effect
combin
therapi
mab
drug
remdesivir
could
ideal
therapeut
option
evalu
requir
confirm
efficaci
combin
therapi
technolog
avail
make
fulli
human
antibodi
human
singlechain
antibodi
huscfv
humanizednanobodi
singledomain
antibodi
sdab
vhvhh
travers
across
membran
virusinfect
cell
tran
bodi
bind
interfer
biolog
activ
replic
viru
protein
consequ
lead
inhibit
viru
replic
exampl
includ
tran
bodi
influenza
viru
hepat
c
viru
ebola
viru
dengu
viru
thu
possibl
gener
tran
bodi
cov
intracellular
protein
papainlik
proteas
plpro
cysteinelik
proteas
nonstructur
protein
nsp
pivot
cov
replic
transcript
safe
nonimmunogen
broadli
effect
passiv
immun
covexpos
subject
treatment
infect
patient
suitabl
anim
model
evalu
vaccin
sarsand
merscov
lack
highli
limit
make
process
vaccin
develop
highli
challeng
develop
effici
anim
model
mimic
clinic
diseas
inform
pathogenesi
well
develop
vaccin
therapeut
cov
sever
anim
model
evalu
sarsand
mer
cov
includ
mous
guinea
pig
hamster
ferret
rabbit
rhesu
macaqu
marmoset
cat
earli
effort
direct
develop
anim
model
sarscov
specif
viru
receptor
sarscov
major
hindranc
effort
later
sarscov
transgen
mous
model
develop
introduc
gene
mous
genom
first
anim
model
use
develop
merscov
vaccin
rhesu
macaqu
infect
anim
show
clinic
symptom
increas
bodi
temperatur
piloerect
cough
hunch
postur
reduc
food
intak
anoth
frequent
use
anim
model
merscov
common
marmoset
wherein
viru
caus
lethal
pneumonia
humor
cellmedi
immun
could
detect
rhesu
macaqu
common
marmoset
follow
merscov
immun
hamster
potenti
model
studi
cov
patholog
pathogenesi
vaccin
efficaci
attenu
cov
vaccin
studi
mice
attempt
develop
anim
model
merscov
mice
hamster
ferret
face
limit
due
inabl
merscov
replic
respiratori
tract
speci
small
anim
mice
hamster
resist
natur
infect
merscov
suscept
sarscov
genet
modifi
human
structur
eg
human
mice
transgen
express
ascertain
suscept
merscov
infect
alter
mous
genom
use
geneedit
tool
could
make
anim
suscept
cov
infect
viru
replic
genet
engin
use
gener
merscov
mous
model
use
evalu
novel
merscov
vaccin
drug
compar
larg
anim
model
small
anim
mice
rabbit
prefer
due
lower
cost
eas
manipul
readili
avail
efficaci
method
studi
need
recogn
suitabl
model
emerg
identifi
receptor
affin
studi
diseas
manifest
pathologiesvir
pathogenesi
associ
experiment
inocul
viru
mice
rat
model
well
examin
virusspecif
immun
respons
protect
would
facilit
preclin
evalu
candid
vaccin
drug
sever
permiss
cell
line
hcov
includ
monkey
epitheli
cell
line
use
neutral
assay
assess
neutral
titer
antibodi
prepar
goat
lung
cell
alpaca
kidney
cell
dromedari
umbil
cord
cell
found
permiss
merscov
sarscov
protein
found
mediat
entri
hepatoma
cell
line
target
neutral
antibodi
virusinfect
patient
advanc
exvivo
tracheobronchi
tissu
mimick
epithelium
conduct
airway
use
human
cov
moreov
vlp
display
sarscov
protein
found
compet
entri
permiss
cell
transfect
cell
overexpress
viru
receptor
isol
attempt
vero
cell
human
liver
cancer
cell
pseudotyp
virionsvlp
encod
report
system
gfp
luciferas
use
quantif
evalu
effect
mab
drug
inhibit
cellular
entri
cov
assay
use
pseudotyp
virionsvlp
perform
facil
sinc
use
infecti
viru
safeti
concern
passiv
immun
antibodi
possibl
antibodydepend
enhanc
ade
viru
replic
antibodi
modifi
fc
fragment
without
fc
fragment
eg
human
singlechain
antibodi
scfv
fab
f
safe
altern
sever
mab
fulli
human
human
target
nonrbd
well
domain
cov
gener
test
cell
cultur
virusneutr
capabl
well
anim
model
prophylact
postexposur
efficaci
antibodi
could
use
tool
also
develop
vaccin
therapeut
drug
antivir
inhibitor
data
anim
cov
vaccin
suggest
system
humor
cellmedi
immun
respons
induc
parenter
administr
may
adequ
prevent
respiratori
tract
infect
respiratori
mucosa
initi
site
cov
infect
transmiss
mucos
immun
use
intranas
vaccin
could
effect
strategi
prophylaxi
induct
mucos
system
immun
respons
molecular
mechan
mucos
system
immunolog
factor
differ
difficult
predict
surrog
marker
cov
efficaci
best
surrog
assay
protect
well
herd
immun
toward
differ
cov
infect
warrant
detail
investig
main
measur
clinic
manag
focus
allevi
clinic
symptom
support
care
therapeut
option
could
evalu
use
includ
molecul
bind
viru
molecul
inhibitor
target
specif
enzym
involv
viral
replic
transcript
smallmolecul
inhibitor
target
helicas
essenti
proteas
protein
viru
host
cell
proteas
inhibitor
host
cell
endocytosi
inhibitor
sirna
antisens
rna
ribozym
neutral
antibodi
mab
target
host
receptor
interfer
rbd
antivir
peptid
target
natur
product
long
list
anticov
agent
mostli
preclin
compound
yet
evalu
agent
agent
phase
iii
trial
includ
remdesivir
oseltamivir
hiv
proteas
inhibitor
lopinavir
ritonavir
darunavir
cobicistat
mani
exist
mersandor
sarscov
inhibitor
screen
efficaci
rnadepend
rna
polymeras
rdrp
sequenc
shown
ident
sarscov
critic
find
sinc
drug
develop
sarscov
rdrp
might
show
similar
efficaci
sarscov
rdrp
protein
consid
major
target
design
cov
antivir
therapi
protein
inhibitor
cleavag
inhibitor
neutral
antibodi
blocker
sirna
fusion
core
blocker
proteas
inhibitor
therapeut
strategi
shown
potenti
vitro
vivo
anticov
activ
compar
even
though
vitro
studi
perform
agent
shown
efficaci
lack
suffici
support
due
lack
random
anim
human
trial
henc
limit
use
henc
necessari
support
extens
anim
human
trial
requir
therapeut
becom
use
bind
affect
balanc
reninangiotensin
system
ra
potenti
lead
exacerb
sever
pneumonia
thu
specul
acei
angiotensin
receptor
inhibitor
might
abl
reduc
pulmonari
inflammatori
respons
therebi
reduc
mortal
guidanc
control
might
base
exist
measur
mer
sar
precaut
due
unknown
natur
new
cov
main
treatment
mechan
ventil
icu
admiss
symptomat
support
care
recommend
sever
case
furthermor
rna
synthesi
inhibitor
like
tdf
remdesivir
neuraminidas
inhibitor
peptid
antiinflammatori
drug
abidol
chines
tradit
medicin
lianhuaqingwen
shufengjiedu
capsul
could
promis
treatment
howev
clinic
trial
requir
confirm
safeti
efficaci
major
limit
factor
quest
identifi
ideal
vaccin
therapeut
agent
time
may
take
month
even
sever
year
research
develop
produc
standard
evalu
approv
commerci
therapeut
agent
henc
current
effort
direct
toward
identifi
evalu
drug
immunotherapeut
proven
efficaci
virus
similar
time
requir
drug
discoveri
program
develop
evalu
obtain
approv
new
potent
agent
could
take
year
present
scenario
develop
new
therapeut
agent
feasibl
option
regard
avail
time
anoth
option
repurpos
broadli
act
antivir
drug
use
viral
infect
drug
advantag
easi
avail
known
pharmacokinet
pharmacodynam
properti
solubl
stabil
side
effect
also
wellestablish
dose
regimen
repurpos
drug
potenti
therapeut
option
manag
cov
infect
repurpos
drug
lopinavir
ritonavir
possess
vitro
antimerscov
activ
vivo
studi
conduct
common
marmoset
nonhuman
primat
model
show
anim
treat
lopinavirritonavir
better
outcom
untreat
anim
combin
lopinavirritonavir
evalu
mer
miracl
trial
two
proteas
inhibitor
lopinavir
ritonavir
combin
ribavirin
found
associ
favor
clinic
respons
sar
patient
indic
therapeut
efficaci
earli
attempt
evalu
repurpos
drug
control
trial
ritonavirboost
lopinavir
therapi
regist
hospit
patient
china
oral
administr
neuraminidas
inhibitor
oseltamivir
use
empir
drug
suspect
case
china
hospit
even
though
evid
efficaci
recent
vitro
antivir
efficaci
approv
drug
ribavirin
penciclovir
nitazoxanid
nafamostat
chloroquin
compar
two
broadspectrum
antivir
drug
remdesivir
favipiravir
among
evalu
drug
remdesivir
chloroquin
found
highli
effect
control
vitro
studi
also
point
three
nucleosid
analog
ribavirin
penciclovir
favipiravir
may
signific
vivo
antivir
effect
sinc
higher
concentr
requir
reduc
viral
infect
vitro
remdesivir
chloroquin
use
treatment
diseas
welldefin
safeti
profil
henc
drug
use
evalu
efficaci
patient
novel
cov
infect
achiev
develop
vaccin
therapeut
agent
sarsand
merscov
well
recent
ongo
progress
facilit
develop
effect
vaccin
therapeut
emerg
viru
howev
present
scenario
warrant
need
implement
robust
prevent
control
measur
due
potenti
nosocomi
infect
need
reli
exclus
prevent
measur
sinc
consider
time
requir
effort
develop
new
vaccin
antivir
agent
becom
fruit
research
search
effect
suitabl
vaccin
candid
therapeut
control
deadli
effect
vaccin
specif
antivir
drug
henc
reli
exclus
enforc
strict
prevent
control
measur
minim
risk
possibl
diseas
transmiss
result
obtain
recent
conduct
vitro
studi
promis
sinc
drug
remdesivir
chloroquin
found
highli
effect
control
infect
direct
clinic
trial
conduct
among
patient
infect
sinc
drug
use
treat
diseas
wellestablish
safeti
profil
make
evalu
drug
much
easier
protein
consid
key
viral
antigen
develop
cov
vaccin
shown
sever
preclin
studi
although
research
progress
improv
prevent
treatment
control
document
clinic
data
differ
therapeut
approach
cov
scarc
research
direct
toward
studi
suitabl
anim
model
analyz
replic
transmiss
pathogenesi
